Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanfacine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.53 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanfacine SCHEMBL1173133 | 1.00 | ADRA2A (0.53) | ADRA2AKMT2AGMNNMAPTBLM | |
| Guanfacine SCHEMBL35094 | 0.98 | KMT2A (0.54) | ADRA2AKMT2AGMNNMAPTBLM | |
| Guanfacine SCHEMBL438188 | 0.95 | AKR1B1 (0.53) | ADRA2AKMT2AGMNNMAPTBLM | |
| Guanfacine SCHEMBL5539292 | 0.92 | KMT2A (0.49) | ADRA2AKMT2AGMNNMAPTBLM | |
| Guanfacine SCHEMBL436700 | 0.90 | AKR1B1 (0.45) | ADRA2AKMT2AGMNNMAPTBLM | |
| Guanfacine SCHEMBL20897969 | 0.88 | AKR1B1 (0.46) | ADRA2AKMT2AGMNNMAPTBLM | |
| Guanfacine SCHEMBL790727 | 0.88 | AKR1B1 (0.46) | ADRA2AKMT2AGMNNMAPTBLM | |
| Guanfacine SCHEMBL437682 | 0.88 | MAPT (0.43) | ADRA2AKMT2AGMNNMAPTBLM | |
| Guanfacine SCHEMBL27913309 | 0.88 | AKR1B1 (0.50) | ADRA2AKMT2AGMNNMAPTBLM | |
| SCHEMBL20909489 | 0.88 | P2RX7 (0.47) | ADRA2AKMT2AGMNNMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2842 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719368-A1 | INJECTABLE GUANFACINE FORMULATIONS AND METHODS | Cumberland Pharmaceuticals Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20250302887-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-10-02 | — | — | US | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| CN-120091700-A | Trans perovskite solar cell and preparation method thereof | 华彩光能科技(云南)有限公司 | 2025-06-03 | — | — | CN | claimed |
| WO-2025092882-A1 | COMBINATION OF A NORADRENERGIC α2A RECEPTOR AGONIST AND A NOREPINEPHRINE DOPAMINE REUPTAKE INHIBITOR AND USE THEREOF | IGNIS THERAPEUTICS (SUZHOU) LIMITED (CN) | 2025-05-08 | — | — | WO | claimed |
| WO-2025078446-A1 | MICROFLUIDIC DEVICE AND METHOD THEREOF FOR RAPID ASSAYS IN SAMPLES | OLSSON CARL (SE) | 2025-04-17 | — | — | WO | claimed |
| US-20250090602-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-03-20 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| CN-114994196-B | High performance liquid chromatography separation method for guanfacine hydrochloride intermediate 2, 6-dichlorophenylacetic acid and impurities | 上海应用技术大学 | 2024-12-31 | — | — | CN | claimed |
| US-12178804-B2 | Salts of cycloserine compounds and applications thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2024-12-31 | — | — | US | claimed |
| EP-1351668-A1 | SUSTAINED RELEASE PHARMACEUTICAL DOSAGE FORMS WITH MINIMIZED PH DEPENDENT DISSOLUTION PROFILES | Shire Laboratories Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030158261-A1 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | SUPERNUS PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | claimed |
| US-20030135128-A1 | Electroencephalography based systems and methods for selecting therapies and predicting outcomes | MYND ANALYTICS, INC., A CALIFORNIA CORPORATION | 2003-07-17 | — | — | US | claimed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | claimed |
| WO-2003005899-A2 | ELECTROENCEPAHLOGRAPHY BASED SYSTEMS AND METHODS FOR SELECTING THERAPIES AND PREDICTING OUTCOMES | CNS RESPONSE, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| WO-2002058676-A1 | SUSTAINED RELEASE PHARMACEUTICAL DOSAGE FORMS WITH MINIMIZED PH DEPENDENT DISSOLUTION PROFILES | SHIRE LABORATORIES, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| US-6287599-B1 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | SHIRE LABORATORIES, INC. | 2001-09-11 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |